Oppenheimer Maintains Outperform on Amgen, Raises Price Target to $450

Benzinga Newsdesk www.benzinga.com Positive 78.7%

Neg 0% Neu 0% Pos 78.7%

Oppenheimer analyst Jay Olson maintains Amgen (NASDAQ:AMGN) with a Outperform and raises the price target from $400 to $450.